Skip to main
PODD
PODD logo

Insulet (PODD) Stock Forecast & Price Target

Insulet (PODD) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 41%
Buy 53%
Hold 6%
Sell 0%
Strong Sell 0%

Bulls say

Insulet has demonstrated a significant opportunity in the insulin pump market, bolstered by its innovative Omnipod system, which offers a user-friendly mobile-operated device that has gained traction with approximately 500,000 users since its FDA approval in 2005. The company's ongoing emphasis on improving gross margins and leveraging its business model is expected to enhance operational income and earnings per share (EPS), supported by projections of operating margin expansion in the coming years. Insulet's strong positioning, characterized by its differentiated product offering and first-mover advantage in the Type 2 diabetes market, presents a favorable outlook for sustained growth in a competitive industry.

Bears say

The projected operating income for Insulet in 2026 has been revised downward to $549.3 million, reflecting a decrease from the previously estimated $561.0 million, alongside a reduction in earnings per share (EPS) expectations to $5.74 from $6.09. The company faces potential competitive pressures if rival products are introduced to the market before Insulet can secure its position within the diabetes management community, which may hinder its ability to meet future performance expectations. Additionally, a consistent reduction in cost of goods sold (COGS) is essential for sustaining its business model, highlighting ongoing financial challenges that could negatively impact profitability.

Insulet (PODD) has been analyzed by 17 analysts, with a consensus rating of Buy. 41% of analysts recommend a Strong Buy, 53% recommend Buy, 6% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Insulet and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Insulet (PODD) Forecast

Analysts have given Insulet (PODD) a Buy based on their latest research and market trends.

According to 17 analysts, Insulet (PODD) has a Buy consensus rating as of Oct 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $342.35, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $342.35, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Insulet (PODD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.